Table 2: summary of findings table for Nitazoxanide versus placebo in HIV-infected and -exposed children with cryptosporidial diarrhoea |
||||||
Patient or population: HIV-infected and
HIV-exposed children with cryptosporidial diarrhoea |
||||||
Outcomes |
Illustrative comparative risks+ (95% CI) |
Relative effect |
No of Participants |
Certainty of the evidence |
Comments |
|
Assumed risk |
Corresponding risk |
|||||
Placebo |
Nitazoxanide |
|||||
Clinical cure |
See comment |
See comment |
Not estimable |
50 |
⊕⊕⊝⊝ |
N/A |
All-cause mortality |
See comment |
See comment |
Not estimable |
50 |
⊕⊕⊝⊝ |
N/A |
+The basis for the assumed risk is the control group risk across the included studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 1 Downgraded by two points for imprecision: only one small study reported on this outcome |
||||||
GRADE Working Group grades of evidence |